Healthcare Private Placement and M&A Transactions Review Week Ending July 9, 2023

TrueBinding: The company raised $57.7 million of venture funding from undisclosed investors on July 5, 2023. The company is a developer of antibody drugs for immune-oncology and other disease areas.

Bryn Pharma: The company raised $26.7 million of venture funding from Fourward Ventures and other undisclosed investors on July 5, 2023. The company is an operator of a biotechnology business intended to offer nasal-based epinephrine for anaphylaxis.

Actym Therapeutics: The company raised $11.2 million of venture funding from undisclosed investors on July 6, 2023. The company is a developer of immuno-oncology therapeutics designed to offer biologics to treat cancer.

Camena Bioscience: The company raised GBP 8.1 million of Series A venture funding in a deal led by Mercia Asset Management on July 3, 2023, putting the company’s pre-money valuation at GBP 12.3 million. Twist Bioscience and Northern Venture Trust also participated in the round. The company is a developer of DNA synthesis technology designed to bring new applications to the market.

Verismo Therapeutics: The company raised KRW 13 billion of venture funding from HLB innoVation on July 6, 2023. The company is a developer of cancer therapeutics designed to improve persistence and efficacy against solid tumor models.

Tribun Health: The company is in the process of raising an estimated EUR 6 million of venture funding as of July 6, 2023. The company is a developer of diagnostic imaging software designed to provide digital transformation of a cancer diagnosis.

S4 Medical: The company raised $6.5 million of venture funding in a deal led by JobsOhio Growth Capital on July 6, 2023. The company is a developer of a novel medical device designed for use in cardiac procedures to treat atrial fibrillation.

Gliknik: The company raised $5.4 million of convertible debt financing from undisclosed investors on July 7, 2023. The company is an operator of a biopharmaceutical business that is developing products to treat cancer and autoimmune diseases.

GenSensor: The company raised EUR 2 million of venture funding from GO Capital (France), Sodero Gestion and Bpifrance on July 4, 2023. The company is a developer a genomic-based monitoring system to optimize in-line bioproduction.

Biome Dx: The company raised venture funding from undisclosed investors on July 5, 2023. The company is a developer of microbiome diagnostic products intended to assist in detecting cancer.

Yourgene Health / Novacyt: Yourgene Health reached a definitive agreement to be acquired by Novacyt for GBP 16.7 million on July 3, 2023. Yourgene Health is a molecular diagnostics company.

CLAP / ABF Advanced Treatment Concierge: The business unit of CLAP was acquired by ABF Advanced Treatment Concierge for an undisclosed amount on July 6, 2023. CLAP is a provider of cancer treatment services based in Chuo-ku, Japan.

Devana Solutions / RealTime Software Solutions: Devana Solutions was acquired by RealTime Software Solutions, via its financial sponsor LLR Partners, through an LBO on July 6, 2023 for an undisclosed amount. Devana Solutions is a developer of cloud-based performance metrics tracking platforms intended for the clinical trial industry.

EDP Biotech / New Day Diagnostics: EDP Biotech was acquired by New Day Diagnostics for an undisclosed amount on July 6, 2023. EDP Biotech is an in vitro diagnostics clinical research organization service provider intended to develop and commercialize immunodiagnostic tests.

Somnoware / ResMed: Somnoware was acquired by ResMed for an undisclosed amount on July 5, 2023. Somnoware is a developer of a sleep disorder management platform designed to assist physicians in managing patients to achieve improved sleep outcomes.